Samsung Bioepis Launches Aflibercept Biosimilar OPUVIZ Across European Markets

Samsung Bioepis's commercial rollout of OPUVIZ, its aflibercept biosimilar referencing Eylea, signals a measurable shift in European ophthalmology biosimilar supply, and raises immediate questions for manufacturing operations teams managing fill-finish capacity and cold-chain logistics for intravitreal injectables.

OPUVIZ becomes the fifth biosimilar Samsung Bioepis has directly commercialized in Europe, a portfolio milestone that reflects both the company's scaled regulatory infrastructure and the accelerating approval cadence for ophthalmology biologics under EMA biosimilar guidance. Unlike earlier therapeutic areas where biosimilar uptake was gradual, ophthalmology has seen procurement bodies move faster, compressing the window between launch and formulary inclusion.

For QA directors and regulatory affairs leads, the intravitreal route of administration places OPUVIZ in a high-scrutiny sterility assurance category. Aflibercept formulations require validated aseptic processing lines, container-closure integrity testing aligned with ICH Q10 quality system expectations, and extractables and leachables data that regulators have increasingly scrutinized at pre-approval inspections. Any manufacturing partner or contract fill-finish site supporting European supply will need documentation packages consistent with 21 CFR Part 211 equivalents under EudraLex Volume 4 GMP requirements.

Market access teams across European health systems will be tracking OPUVIZ's pricing position relative to Eylea and competing aflibercept biosimilars already in or approaching the market. The ophthalmology biosimilar segment is no longer a single-entrant space; procurement negotiations in tendering markets will increasingly hinge on supply reliability and batch release timelines as much as unit cost.

The pace of Samsung Bioepis's European biosimilar commercialization, five products now directly launched, also points to a maturing internal pharmacovigilance and post-marketing surveillance infrastructure, a capability that plant heads and regulatory leads at competing manufacturers will be benchmarking against their own European launch readiness.

The measurable outcome to track is OPUVIZ's formulary uptake rate across tendering markets over the next four quarters, which will serve as a leading indicator for how quickly ophthalmology biosimilars can displace reference product volumes at scale.

Source: Media4Growth via Indian Pharma Post, 31 May 2026.